Showing 2151-2160 of 6036 results for "".
- Alcon to Highlight New Data at ASCRS Demonstrating Innovations Designed to Optimize Patient Outcomeshttps://modernod.com/news/alcon-to-highlight-new-data-at-ascrs-demonstrating-innovations-designed-to-optimize-patient-outcomes/2482199/Alcon will showcase approximately 100 company-supported and investigator-led data presentations demonstrating its latest innovative efforts aimed at optimizing patient outcomes at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, April 5-8, in Boston. In additio
- Phase 1b/2a Trial of Exonate's Eye Drop Demonstrates Safety and Biological Activity in Treatment of DR and DMEhttps://modernod.com/news/phase-1b2a-trial-of-exonates-eye-drop-demonstrate-safety-and-biological-activity-in-treatment-of-dr-and-dme/2482148/UK-based Exonate announced data from a phase 1b/2a trial for lead candidate EXN407 demonstrating safety and tolerability of the drug candidate, as well as clear indications of biological activity, according to a company news release. The data position the company for further development
- Alcon Canada Launches TOTAL30 Multifocal Contact Lenses for Reusable Lens Patients with Presbyopiahttps://modernod.com/news/alcon-canada-launches-total30-multifocal-contact-lenses-for-reusable-lens-patients-with-presbyopia/2482093/Alcon announced the launch of TOTAL30 Multifocal in Canada, the first and only monthly water gradient multifocal contact lens. The new TOTAL30 Multifocal lens is designed to help digital device dryness by utilizing a proprietary water gradient technology to deliver nearly
- Mireca Medicines Awarded Nearly $1 Million from the Foundation Fighting Blindness to Develop Treatments for IRDshttps://modernod.com/news/mireca-medicines-awarded-nearly-1-million-from-the-foundation-fighting-blindness-to-develop-treatments-for-inherited-retinal-diseases/2482085/Mireca Medicines announced it has received a $989,000 'Translational Research Acceleration Program Award' from Foundation Fighting Blindness that will permit the company to further advance the preclinical development of its lead product MM238. In a news
- Mass Eye and Ear: Retinal Imaging and Genetics Data Used to Predict Future Disease Riskhttps://modernod.com/news/mass-eye-and-ear-retinal-imaging-and-genetics-data-used-to-predict-future-disease-risk/2482082/In a new study published in Science Translational Medicine, physician-researchers from Mass Eye and Ear, and the Broad Institute of MIT and Harvard, combined retinal imaging, genetics and big data to estimate how likely a person is to develop eye and systemic diseases in the future.
- Azura Ophthalmics Announces Positive Results from Phase 2 Clinical Trial of AZR-MD-001 in Patients with Contact Lens Discomforthttps://modernod.com/news/azura-ophthalmics-announces-positive-results-from-phase-2-clinical-trial-of-azr-md-001-in-patients-with-contact-lens-discomfort/2482017/Azura Ophthalmics announced positive topline efficacy and safety results from a phase 2 study of AZR-MD-001 in patients with Contact Lens Discomfort (CLD) who could not comfortably wear their lenses as desired and who demonstrated signs of meibomian gland dysfunction (MGD). The trial met its prim
- New "Eye Chart" App Designed to Address Common Challenges in Near Vision Testinghttps://modernod.com/news/new-eye-chart-app-designed-to-address-common-challenges-in-near-vision-testing/2481995/A new app aims to address common challenges encountered in near vision testing. The "Eye Chart" app, which was developed by Michael Ullman, MD, a cornea specialist at Ullman Eye Consultants in Pensacola, Florida, leverages the iPhone's TrueDepth camera to me
- LENZ Therapeutics and Graphite Bio Announce Mergerhttps://modernod.com/news/lenz-therapeutics-and-graphite-bio-announce-merger/2481971/LENZ Therapeutics and Graphite Bio announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The lead programs of the combined company will address presbyopia. The combined company is expected to trade on Nasdaq under the t
- Atsena Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Gene Therapy for LCA1https://modernod.com/news/atsena-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-rmat-designation-for-gene-therapy-for-lca1/2481966/Atsena Therapeutics announced the FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to ATSN-101, the company’s lead investigational gene therapy for patients with Leber congenital amaurosis caused by biallelic mutations in GUCY2D (LCA1). RMAT desi
- AffaMed Therapeutics Announces Positive Topline Results from Real-World Study in China Evaluating Dextenza in Patients after Cataract Surgeryhttps://modernod.com/news/affamed-therapeutics-announces-positive-topline-results-from-real-world-study-in-china-evaluating-dextenza-in-patients-after-cataract-surgery/2481932/AffaMed Therapeutics announced positive topline results from the real-world study conducted in the Boao Lecheng Pilot Zone in Hainan, China, to evaluate the safety and efficacy of Dextenza (0.4 mg dexamethasone ophthalmic insert) for the treatment of ocular inflammation and pain followi